



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

Twenty-First Board Meeting
Geneva, 28-30 April 2010

GF/B21/17
Revision 1
For information

ELECTRONIC DECISION POINTS

OUTLINE:

The purpose of this paper is to provide an overview of the Board's decisions that were carried out electronically since the adjournment of the Twentieth Meeting of the Board and until the start of the Twenty-First Meeting.

Approval of Phase 2 Funding for November 2009

Confirmed 19 November 2009

Decision Point GF/B20/EDP1:

The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard.

The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.

SCHEDULE A

	Country, Disease, Round	Grant Number(s)	CCM Requested Amount (Total Phase 2 in US\$)	Recommended Funding Amount (Incremental in US\$)	Recommendation Category
1.	Democratic Republic of Congo, TB Round 5	ZAR-506-G04-T	19,056,000	14,505,000 ¹	Conditional Go
2.	Democratic Republic of Congo, TB Round 6	ZAR-607-G05-T			
3.	Eritrea, Malaria Round 6	ERT-607-G05-M	8,129,293	6,358,135	Go
4.	Rwanda, HIV Round 6	RWN-607-G08-H	27,349,463	19,244,914	Conditional Go
5.	Syria, TB Round 6	SYR-607-G01-T	5,038,762	2,799,078	Conditional Go
Total				US\$ 42,907,127	

This decision does not have material budgetary implications.

¹ Please note that the CCM submitted a request to consolidate Round 5 and Round 6 TB grants to one grant.

Approval of Continuity of Services for Haiti TB Round 3

Confirmed 19 November 2009

Decision Point GF/B20/EDP2:

The Board approves additional funding for two years for the Continuity of Services for the proposal listed in Schedule B and described in Annex 1, with the clear understanding that the amount approved is an upper ceiling rather than a final funding amount, and based on the understanding that the Secretariat shall pursue implementation arrangements for such proposal consistent with the recommendation set forth in Annex 1.

SCHEDULE B

	Country, Disease, Round	Grant Number	CCM Requested Amount (in US\$)	Recommended Funding Amount (Incremental in US\$)
1.	Haiti, TB Round 3	HTI-304-G04-T	1,845,932	413,096

This decision does not have material budgetary implications.

Approval of Phase 2 Funding for Mozambique Malaria Round 9

Confirmed 19 November 2009

Decision Point GF/B20/EDP3:

The Board approves additional funding for the Phase 2 period of the Round 6 Mozambique Malaria grant (MOZ-607-G06-M) as a Conditional Go in the amount of up to US\$ 7,762,108, subject to TRP clarifications and conditions within a limited timeframe, and also subject to possible additional conditions to be cleared by the Secretariat.

The Board reaffirms that the maximum funding amount for Phase 2 of this grant shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.

This decision does not have material budgetary implications.

Global Fund Privileges and Immunities

Confirmed 14 December 2009

Decision Point GF/B20/EDP4:

The Board recognizes the importance of States granting to the Global Fund such privileges and immunities as necessary for the effective exercise of its functions and efficient use of its resources. The Board recommends that States consider granting privileges and immunities to the Global Fund by:

- applying domestic legislation that specifically confers on the Global Fund status, capacities, privileges and immunities equivalent to those enjoyed by international organizations within their respective legal systems, and/or
- adhering to the Agreement on Privileges and Immunities of the Global Fund to Fight AIDS, Tuberculosis, and Malaria set out in Attachment 1 - Revision 1 of the Policy and Strategy Committee's Report to the Board (GF/B20/4), pursuant to Article 8 of that Agreement;

and requests the Secretariat to report back to the Board periodically on what measures states have taken in response to this decision.

This decision does not have material budgetary implications

Approval of Phase 2 Funding for December 2009

Confirmed 17 December 2009

Decision Point GF/B20/EDP5:

The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard.

The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.

SCHEDULE A

	Country, Disease, Round	Grant Number(s)	CCM Requested Amount (Total Phase 2 in US\$ or Euros)	Recommended Funding Amount (Incremental in US\$ or Euros)	Recommendation Category
1.	Bulgaria, TB, Round 6	BUL-607-G02-T	Euros 7,599,858	Euro 7,175,629 = US\$10,816,543 ²	Go
2.	Cuba, HIV, Round 6	CUB-607-G02-H	US\$ 18,420,923	US\$ 18,610,923	Go
3.	Georgia, HIV, Round 6	GEO-607-G06-H	US\$ 5,255,135	US\$ 4,726,671	Go
4.	Moldova, HIV, Round 6	MOL-607-G03-H	US\$ 9,525,291	US\$ 9,526,838	Go
5.	Pakistan, TB, Round 6	PKS-607-G06-T	US\$ 15,117,192	US\$11,143,952	Go
6.	Pakistan, TB, Round 6	PKS-607-G07-T	US\$ 16,519,101	US\$12,637,400	Go
7.	Philippines, Malaria, Round 6	PHL-607-G07-M	US\$ 6,574,505	US\$ 3,497,900	Conditional Go
8.	Togo,	TGO-607-	Euro	Euro 1,898,683 = US\$	Go

² The Bulgaria Round 6 TB, Togo Round 6 Malaria and Togo Round 6 TB proposals were approved in Euro and the respective CCMs have requested Phase 2 funding in Euro. To give the Board the most up-to-date picture of what the EUR/USD equivalent is at the time of the Phase 2 submission, the recommended incremental funding amount has been computed in USD using the rate of exchange that is published by the International Monetary Fund on its website on 1 December 2009, 2009 (Euro1 = US\$1.5074).

	Malaria, Round 6	G06-M	1,909,188	2,862,075 ³	
9.	Togo, TB, Round 6	TGO-607- G07-T	Euro 2,319,788	Euro 2,186,849 = US\$ 3,296,456 ³	Go
10.	Vietnam, HIV, Round 6	VTN-607- G04-H	US\$ 16,697,157	US\$ 15,774,158	Conditional Go
11.	Vietnam, TB, Round 6	VTN-607- G05-T	US\$ 8,121,620	US\$ 7,444,658	Conditional Go
Total				US\$ 100, 337, 574	

This decision does not have material budgetary implications.

³ Where the Board approves additional funding for a period greater than two years, the Secretariat is required to commit that additional funding limited to two years. A third year of additional funding may subsequently be committed by the Secretariat, not earlier than eighteen months from the start of additional funding, conditional upon the availability of funding.

Approval of Funding for Continuity of Services for Cameroon HIV Round 3

Confirmed 17 December 2009

Decision Point GF/B20/EDP6:

The Board approves additional funding for two years for the Continuity of Services for the proposal listed in Schedule B and described in Annex 1, with the clear understanding that the amount approved is an upper ceiling rather than a final funding amount, and based on the understanding that the Secretariat shall pursue implementation arrangements for such proposal consistent with the recommendation set forth in Annex 1.

SCHEDULE B

	Country, Disease, Round	Grant Number	CCM Requested Amount (in US\$ or Euros)	Recommended Funding Amount (Incremental in US\$ or Euros)
1.	Cameroon, HIV, Round 3	CMR-304-G01-H	18,004,361 Euros	12, 492,000 Euros = US\$ 18,830,441

This decision does not have material budgetary implications.

Approval of Phase 2 Funding for Mozambique HIV Round 6

Confirmed 17 December 2009

Decision Point GF/B20/EDP7:

The Board approves additional funding for the Phase 2 period of the Round 6 Mozambique HIV grant (MOZ-607-G05-H) as a Go in the amount of up to US\$ 47,292,469, subject to TRP clarifications and conditions within a limited timeframe, and also subject to possible additional conditions to be cleared by the Secretariat.

The Board reaffirms that the maximum funding amount for Phase 2 of this grant shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.

This decision does not have material budgetary implications.

Appointment of Chairs of Committees

Confirmed 31 December 2009

Decision Point GF/B20/EDP8:

The Board approves the appointment of the following persons as Chairs of the following Committees:

Dr. Suwit Wibulpolprasert for the Policy and Strategy Committee;
Mr. Peter van Rooijen for the Finance and Audit Committee;
Ms. Michele Moloney-Kitts for the Portfolio and Implementation Committee;
Dr. Bobby John for the Ethics Committee; and
Dr. Lesley Ramsammy for the Affordable Medicines Facility for Malaria (AMFm) Ad Hoc Committee.

The Chair of each Committee is appointed for the period from the date of this decision until the adjournment of the first Board meeting of 2011.

This decision does not have material budgetary implications

Approval of Phase 2 Funding for January 2010

Confirmed 28 January 2010

Decision Point GF/B20/EDP9:

The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard. Approval is also subject to paragraph 3.c. of the revised Comprehensive Funding Policy (GF/B20/DP9).⁴

The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.

SCHEDULE A

	Country, Disease, Round	Grant Number(s)	CCM Requested Amount (Total Phase 2 in US\$)	Approved Funding Amount (Incremental in US\$)	Recommendation Category
1.	Cambodia, Malaria Round 6	CAM-607-G10-M	17,912,280	14,314,077	Conditional Go
2.	Multi Country Africa HIV Round 6	MAW-607-G01-H	24,304,888	19,866,000	Conditional Go
3.	Philippines, HIV Round 6	PHL-607-G08-H	9,624,778	8,026,608	Conditional Go
4.	Sierra Leone, HIV Round 6	SLE-607-G04-H	15,118,702	14,194,664	Go
Total				US\$ 56,401,349	

This decision does not have material budgetary implications.

⁴ Where the Board approves additional funding for a period greater than two years, the Secretariat is required to commit that additional funding limited to two years. A third year of additional funding may subsequently be committed by the Secretariat, not earlier than eighteen months from the start of additional funding, conditional upon the availability of funding

Approval of Phase 2 Funding for February 2010

Confirmed 11 February 2010

Decision Point GF/B20/EDP10:

The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard. Approval is also subject to paragraph 3.c. of the revised Comprehensive Funding Policy (GF/B20/DP9).⁵

The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.

SCHEDULE A

	Country, Disease, Round	Grant Number(s)	CCM Requested Amount (Total Phase 2 in US\$ or Euros)	Approved Funding Amount (Incremental in US\$ or Euros)	Recommendation Category
1.	Bhutan, HIV, Round 6	BTN-607-G03-H	US\$ 2,037,440	US\$1, 440,425	Go
2.	Bhutan, TB, Round 6	BTN-607-G04-T	US\$ 967,190	US\$ 609,791	Go
3.	Indonesia, Malaria, Round 6	IND-607-G06-M	US\$ 29,345,958	US\$ 24,518,770	Go
4.	Zimbabwe, HIV, Round 5	ZIM-509-G10-H	US\$ 27,082,779	US\$ 24,000,864	Conditional Go
5.	Zimbabwe, TB, Round 5	ZIM-509-G08-T	US\$ 2,936,611	US\$ 2,456,521	Conditional Go
Total				US\$ 53,026,371	

This decision does not have material budgetary implications.

⁵ Where the Board approves additional funding for a period greater than two years, the Secretariat is required to commit that additional funding limited to two years. A third year of additional funding may subsequently be committed by the Secretariat, not earlier than eighteen months from the start of additional funding, conditional upon the availability of funding.

Approval of Funding for Continuity of Services for Bolivia HIV Round 3, Comoros HIV Round 3, and Suriname HIV Round 3

Confirmed 11 February 2010

Decision Point GF/B20/EDP11:

The Board approves additional funding for the Continuity of Services for the proposals listed in Schedule B and described in Annex 1, with the clear understanding that the amount approved is an upper ceiling rather than a final funding amount, and based on the understanding that the Secretariat shall pursue implementation arrangements for such proposal consistent with the recommendation set forth in Annex 1.

SCHEDULE B

	Country, Disease, Round	Grant Number	CCM Requested Amount (in US\$ or Euros)	Approved Funding Amount (Incremental in US\$ or Euros)
	Bolivia, HIV, Round 3	BOL-307-G07-H	US\$ 3,449,593	US\$ 837,400
	Comoros, HIV, Round 3	COM-304-G02-H	Euros 13,709 ⁶	US\$ 1, 688
	Suriname, HIV, Round 3	SUR-305-G01-H	US\$ 773,279	US\$ 740,420
	Total			US\$ 1,579,508

This decision does not have material budgetary implications.

⁶ The Comoros CCM submitted the request in Euros; however, the Round 3 HIV grant has been funded in US Dollars. Therefore, the Secretariat is recommending the Incremental amount for the Continuity of Services request in US Dollars.

Approval of Round 9 Appeals

Confirmed 20 February 2010

Decision Point GF/B20/EDP12:

1. The Board approves the following Round 9 proposals recommended for funding by the Independent Appeal Panel in its report dated 8 February 2010, subject to paragraph 2 below:

- i. Pakistan (HIV disease component only) - USD 11,856,124; and
- ii. Ukraine (Tuberculosis) - USD 34,584,205.

2. These Appeal Panel-recommended Round 9 proposals are approved for funding by the Board as 'Category 2' proposals, for an initial two years, under the terms of the Comprehensive Funding Policy and subject to the following:

- a. Satisfactory completion by the applicants of the Technical Review Panel (TRP) clarifications as set out in paragraph 3 below;
- b. the measures associated with funding of Round 9 proposals and national strategy applications set out in Decision GF/B20/DP9; and
- c. The clear understanding that the amounts indicated are upper ceilings subject to adjustment through TRP clarifications and grant negotiations, rather than final approved Phase 1 grant amounts.

3. The applicants for the proposals referred to in paragraph 1 above shall:

- a) provide an initial detailed written response to the clarifications and adjustments requested by the Independent Appeal Panel not later than six weeks after the receipt of either:
 - i) notification in writing by the Secretariat to the applicant of this Board decision; or
 - ii) the findings of the independent budget review (in the case where the Independent Appeal Panel has requested an independent budget review as part of the clarifications process);

and

- b) complete any further clarifications or adjustments, as required by the Chair or Vice-Chair of the TRP, not later than three months from the Secretariat's receipt of the applicant's initial detailed response to the issues raised for clarifications or adjustments (if applicable).

4. The Board notes the Independent Appeal Panel's request to have additional financial analysis support as part of the clarifications process and requests the Secretariat to make the necessary arrangements.

The budgetary implications of this decision are estimated at approximately USD 25,000 for professional fees associated with the independent budget review.

Approval of Round 9 Proposals (Category 2B)

Confirmed 20 February 2010

Decision Point GF/B20/EDP13:

The Board refers to its Decision GF/B20/DP11 regarding approval of Round 9 proposals and approves for funding for an initial two years those Round 9 proposals recommended for funding by the Technical Review Panel (TRP) and identified as 'Category 2B' proposals and as listed in the following table. Such approval is subject to the Comprehensive Funding Policy, satisfactory completion by the applicants of the Technical Review Panel (TRP) clarifications as set out in paragraph 5 of Decision GF/B20/DP11 and the measures associated with funding of Round 9 proposals and national strategy applications set out in Decision GF/B20/DP9.

There are no budgetary implications for this decision.

No.	Applicant type	Applicant	Income level (from Annex 1 in Round 9 Guidelines)	WHO Region	Global Fund Regional Team	Disease	TRP Recommended ¹ Phase 1 Upper ceiling (2 Years) ¹	TRP Recommended ¹ Lifetime Upper ceiling (Up to 5 years) ²
55	CCM	Bosnia & Herzegovina	Lower-middle	EURO	EECA	Tuberculosis	€7,267,274	€15,007,449
56	CCM	Republic	Low	AFRO	WCA	Tuberculosis	€12,167,295	€29,782,006
57	CCM	Colombia	Lower-middle	AMRO	LAC	HIV	€16,659,253	€42,317,779
58	CCM	(Republic of)	Lower-middle	AFRO	WCA	HIV	€10,773,466	€27,447,268
59	CCM	Djibouti	Lower-middle	EMRO	MENA	Malaria	€2,342,193	€8,591,358
60	CCM	Guinea-Bissau	Low	AFRO	WCA	Tuberculosis	€7,179,501	€14,553,382
61	CCM	Kosovo	Lower-middle	EURO	EECA	Tuberculosis	€2,764,907	€5,821,665
62	CCM	Moldova	Lower-middle	EURO	EECA	Tuberculosis	€5,271,784	€10,099,233
63	CCM	Montenegro	Lower-middle	EURO	EECA	HIV	€2,547,414	€5,164,899
Sub-Total: Category 2B Proposals in EURO							€67,013,087	€156,785,027
64	CCM	Angola	Lower-middle	AFRO	SA	Tuberculosis	\$11,364,314	\$25,766,362
65	CCM	Belize	Upper-middle	AMRO	LAC	HIV, incl. CCHSS	\$3,190,410	\$6,053,270
66	CCM	China	Lower-middle	WPRO	EAP	Tuberculosis, incl. CCHSS	\$76,075,195	\$239,855,469
67	RO	OPRECOS	Mixed	AMRO	LAC	HIV	\$17,588,678	\$58,888,550
68	CCM	Democratic Republic of the Congo	Low	AFRO	EA	Tuberculosis, incl. CCHSS	\$110,082,302	\$306,794,269
69	CCM	Ethiopia	Low	AFRO	EA	Tuberculosis, CCHSS only	\$19,383,242	\$38,801,776
70	CCM	Haiti	Low	AMRO	LAC	Tuberculosis	\$12,260,870	\$27,869,547
71	CCM	India	Low	SEARO	SWA	HIV	\$21,000,208	\$78,712,640
72	CCM	India	Low	SEARO	SWA	Malaria	\$38,105,605	\$113,880,179
73	CCM	Iraq	Lower-middle	EMRO	MENA	Tuberculosis	\$14,670,783	\$28,785,292
74	CCM	Kenya	Low	AFRO	EA	Tuberculosis	\$23,662,114	\$50,661,608
75	CCM	Kyrgyz Republic	Low	EURO	EECA	Tuberculosis	\$7,811,886	\$26,273,558
76	CCM	Mozambique	Low	AFRO	SA	HIV, disease part only	\$69,377,979	\$175,774,009
77	CCM	Nicaragua	Lower-middle	AMRO	LAC	Malaria	\$4,299,868	\$8,204,092
78	CCM	Nigeria	Low	AFRO	WCA	Tuberculosis	\$31,515,160	\$113,332,101
79	RO	SADC	Mixed	AFRO	SA	HIV	\$24,587,681	\$44,982,085
80	CCM	Sri Lanka	Lower-middle	SEARO	SWA	HIV, incl. CCHSS	\$19,398,656	\$34,901,359
81	CCM	United Republic of Tanzania	Low	AFRO	EA	Malaria	\$76,050,523	\$173,812,609
82	CCM	The Gambia	Low	AFRO	WCA	Tuberculosis	\$8,049,144	\$15,626,486
83	CCM	Turkmenistan	Lower-middle	EURO	EECA	Tuberculosis, disease part only	\$7,268,169	\$19,186,023
84	CCM	Vietnam	Low	WPRO	EAP	Tuberculosis	\$19,124,977	\$59,392,208
85	CCM	Yemen	Low	EMRO	MENA	Tuberculosis	\$11,136,828	\$24,769,339
Sub-Total: Category 2B Proposals in USD							\$626,065,570	\$1,671,323,831
Total: Category 2B Proposals in USD Equivalent ³							\$719,921,434	\$1,890,910,704

Notes:

- 1 Prior to any reduction arising from the adjustment for efficiency applicable to Phase 1 of Round 9 in accordance with Decision Point GF/B20/DPE
- 2 Prior to any reduction arising from the maximum limit applicable to Phase 2 of Round 9 in accordance with Decision Point GF/B20/DP9
- 3 The USD equivalent of proposal amounts requested in Euro is based on the official UN exchange rate as at 1 February 2010 (USD 1 = EUR 0.714)

Membership of Board Committees

Confirmed 1 March 2010

Board Decision GF/B20/EDP14:

The Board approves the membership of the Board Committees as set out in Annex 1 (Revision 1) attached to this decision. The members of each Committee are appointed for the period from the date of this decision until the adjournment of the first Board meeting of 2011.

There are no material budgetary implications for this decision.

Approval of Phase 2 Funding for March 2010

Confirmed 11 March 2010

Decision Point GF/B20/EDP15:

The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard. Approval is also subject to paragraph 3.c. of the revised Comprehensive Funding Policy (GF/B20/DP9).⁷

The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.

SCHEDULE A

	Country, Disease, Round	Grant Number(s)	CCM Requested Amount (Total Phase 2 in US\$ or Euros)	Approved Funding Amount (Incremental in US\$ or Euros)	Recommendation Category
1.	Cote d'Ivoire, TB, Round 6	CIV-607-G07-T	US\$ 2,817,549	US\$ 2,542,896	Conditional Go
2.	Ethiopia, TB, Round 6	ETH-607-G06-T	US\$ 35,574,710	US\$ 26,475,583	Conditional Go
3.	Egypt, HIV, Round 6	EGY-608-G03-H	US\$ 5,950,197	US\$ 4,917,331	Go
4.	Guinea Bissau, Malaria, Round 6	GNB-607-G04-M	US\$ 8,934,595	US\$ 6,335,149	Conditional Go
5.	Macedonia FYR, HIV, Round 7	MKD-708-G03-H	Euros 3,454,581	Euros 3,371,813= US\$ 4,594,740 ⁸	Go

⁷ Where the Board approves additional funding for a period greater than two years, the Secretariat is required to commit that additional funding limited to two years. A third year of additional funding may subsequently be committed by the Secretariat, not earlier than eighteen months from the start of additional funding, conditional upon the availability of funding.

⁸ The Macedonia FYR Round 6 HIV proposal was approved in Euro and the CCM has requested Phase 2 funding in Euro. To give the Board the most up-to-date picture of what the EUR/USD equivalent is at the time of the Phase 2 submission, the recommended incremental funding amount has been computed in USD using the rate of exchange that is published at www.oanda.com on 1 March 2010 (Euro1 = US\$ 1.36269).

6.	Sri Lanka, HIV, Round 6	SRL-607- G09-H	US\$ 934,350	US\$ 618,117	Go
7.	Sri Lanka, TB, Round 6	SRL-607- G07-T	US\$5,663,689	US\$ 5,017,776	Conditional Go
8.	Zimbabwe, Malaria, Round 5	ZIM-509- G09-M	US\$ 8,750,479	US\$ 6,428,586	Conditional Go
Total				US\$ 56,930,178	

This decision does not have material budgetary implications.

Approval of Rolling Continuation Channel Wave 8 Proposals

Confirmed 13 April 2010

Decision Point GF/B20/EDP16:

1. The Board approves, subject to paragraph 2 below, the Rolling Continuation Channel proposals recommended for funding by the Technical Review Panel (TRP) as ‘Category 2’ which are listed in Annex 1 to the Report of the TRP and the Secretariat on Funding Recommendation for Wave 8 Rolling Continuation Channel Proposals (the “Wave 8 RCC Report”). The Board approves funding for up to three years for each proposal (indicated as “Total 3 Years” in Annex 1 to the Wave 8 RCC Report). The Board’s approval is made with the clear understanding that the grant amounts requested are upper ceilings subject to TRP clarifications and grant negotiations rather than final approved grant amounts. For further clarity, this decision is subject to the revised Comprehensive Funding Policy approved at the Twentieth Board meeting.
2. The applicants whose proposals are recommended for funding as ‘Category 2’ shall:
 - i. provide an initial detailed written response to the requested TRP clarifications and adjustments by no later than four weeks after notification in writing by the Secretariat to the applicant of the Board’s decision; and
 - ii. conclude the TRP clarifications process, as indicated by the written approval of the Chair and Vice Chair of the TRP, not later than two months from the Secretariat’s receipt of the applicant’s initial detailed response to the issues raised for clarification and/or adjustment.
3. The Board declines to approve for funding those proposals categorized by the TRP as ‘Category 3A’ as indicated in Annex 1 to the Wave 8 RCC Report, however such applicants are strongly encouraged to resubmit a revised proposal, taking into account the issues raised by the TRP, for consideration in the final resubmission wave of Rolling Continuation Channel review.
4. The Board declines to approve for funding proposals categorized by the TRP as ‘Category 3B’ as indicated in Annex 1 to the Wave 8 RCC Report, however such applicants are encouraged to resubmit the proposal through the Rounds-Based Channel following major revision.

This decision does not have material budgetary implications.

Approval of Phase 2 Funding for April 2010

Confirmed 16 April 2010

Decision Point GF/B20/EDP17:

The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard. Approval is also subject to paragraph 3.c. of the revised Comprehensive Funding Policy (GF/B20/DP9).

The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.

SCHEDULE A

	Country, Disease, Round	Grant Number(s)	CCM Requested Amount (Incremental in US\$ or Euros)	Approved Funding Amount (Incremental in US\$ or Euros)	Recommendation Category
1.	Burkina Faso, Malaria, Round 7	BUR-708-G07-M	Euro 13,833,661	Euro 11,965,794 = US\$ 16,135,800 ⁹	Conditional Go
2.	South Africa, HIV, Round 6	SAF-607-G06-H	US\$ 47,489,285	US\$ 24,896,406	Conditional Go
3.	Tanzania, TB, Round 6	TNZ-607-G09-T	US\$ 15,425,416	US\$ 12,891,553	Conditional Go
4.	Zanzibar, HIV, Round 6	ZAN-607-G05-H	US\$ 2,077,365	US\$ 1,246,703	Conditional Go
Total				US\$ 55,170,462	

There are no material budgetary implications for this decision.

⁹ The Burkina Faso Round 7 Malaria proposal was approved in Euro and the CCM has requested Phase 2 funding in Euro. To give the Board the most up-to-date picture of what the EUR/USD equivalent is at the time of the Phase 2 submission, the recommended incremental funding amount has been computed in USD using the rate of exchange that is published at www.oanda.com on 1 April 2010 (Euro1 = US\$ 1.34849).

Approval of Phase 2 Funding for Togo Malaria Round 4

Confirmed 16 April 2010

Decision Point GF/B20/EDP18:

The Board acknowledges that the special condition upon which the Board approved the Togo Round 4 Malaria grant to the United Nations Development Programme (UNDP) of the delivery at the end of year 3 of a detailed assessment of program progress and performance was fulfilled later than anticipated in the grant agreement. Although the revised timeline for the program assessment has delayed confirmation that the condition has been fulfilled, in recognition of the subsequent improved program performance of the grant the Board decides to retrospectively approve continued funding for years 4 and 5 of the Togo Round 4 Malaria grant (TGO-405-G05-M).

There are no material budgetary implications for this decision.

Decision to Discontinue Funding for Zambia HIV Round 4

Confirmed 16 April 2010

Decision Point GF/B20/EDP19:

The Board acknowledges that the special condition upon which the Board approved continued funding to the Zambia Round 4 HIV grant to the Ministry of Finance and National Planning of the Government of Zambia required the Principal Recipient to utilize at least fifty per cent (50%) of the funds disbursed from the Global Fund during Year 3 of the Program Term and that an overall rating of B1 or above would be achieved during Year 3 of the Program Term. In recognition that the special condition was not met, the Board decides to discontinue funding for years 4 and 5 of the Zambia Round 4 HIV grant (ZAM-405-G12-H).

There are no material budgetary implications for this decision.